Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that the European ...

The need to establish a fund under the EU budget to support the production of critical medicines in Europe is a conclusion drawn from an analysis of the impact of the war on the availability of ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Orchard Therapeutics, a Kyowa Kirin company, today announced the last patient has been treated in a registrational trial ...

Ashurst’s Paris head is steering the firm through fierce U.S. competition, AI disruption, and rising regulatory pressure amid ...

Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.

EMA & HMA issue recommendations to address vulnerabilities in the supply chain of anti-D immunoglobulins: Amsterdam, The Netherlands Monday, July 7, 2025, 09:00 Hrs [IST] The Euro ...

China has barred European medical device companies from selling to its government in response to EU trade restrictions ...

Can I go to Europe this summer? 2021? The New York Times Article: <a href=" The playlist <a href=" YEAH!!! Europe is open to ...

Shreehas Tambe, CEO & Managing Director, Biocon Biologics said, "The approval of Vevzuo and Evfraxy in Europe underscores our ...

The EC granted conditional approval based on activity seen in a subset of IHC 3+ HER2-positive advanced biliary tract cancer patients in a Phase II trial.

Traditional and new laboratory tools along with advances in AI are outlining a new paradigm in human disease modeling.